The effects of amlodipine and platelet rich plasma on bone healing in rats

Basit Öğe Kaydı
dc.contributor.authorAtalay, Yusuf
dc.contributor.authorBozkurt, Mehmet Fatih
dc.contributor.authorGonul, Yucel
dc.contributor.authorCakmak, Omer
dc.contributor.authorAgacayak, Kamil Serkan
dc.contributor.authorKose, Ibrahim
dc.contributor.authorHazman, Omer
dc.date.accessioned2024-04-24T17:18:27Z
dc.date.available2024-04-24T17:18:27Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: The aim of this study was to evaluate the effects of calcium channel blocker (CCB) amlodipine (AML), platelet rich plasma (PRP), and a mixture of both materials on bone healing. Materials and methods: Fifty-six male Wistar rats were randomly divided into four groups: group A, tibia defect model with no treatment; group B, tibia defect model treated with AML, 0.04 mg daily by oral gavage; group C, tibia defect model treated with local PRP; group D, tibia defect model treated with local PRP and AML, 0.04 mg daily by oral gavage. Results: At day 21, bone healing was significantly better in groups C and D compared to group A (P<0.05), but comparisons showed no statistically significant difference in group B (P>0.05). At day 30, groups B and C showed no statistically significant difference (P>0.05) compared to group A, but bone healing in group D was significantly better than in group A (P<0.05). Statistically, AML did not affect alkaline phosphatase (ALP) activity at 21 and 30 days (P>0.05), but PRP and AML + PRP increased ALP activity statistically (P<0.05). Conclusion: It can be concluded that AML had neither a positive nor a negative effect on bone healing, but when used in combination with PRP, it may be beneficial.en_US
dc.description.sponsorshipAfyon Kocatepe University [13.DIS.01]en_US
dc.description.sponsorshipThis study was supported by the Scientific Research Projects of Afyon Kocatepe University (Project no: 13.DIS.01).en_US
dc.identifier.doi10.2147/DDDT.S80778
dc.identifier.endpage1981en_US
dc.identifier.issn1177-8881
dc.identifier.pmid25897207
dc.identifier.scopus2-s2.0-84929222861
dc.identifier.scopusqualityQ1
dc.identifier.startpage1973en_US
dc.identifier.urihttps://doi.org/10.2147/DDDT.S80778
dc.identifier.urihttps://hdl.handle.net/11468/18786
dc.identifier.volume9en_US
dc.identifier.wosWOS:000352284100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofDrug Design Development and Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAmlodipineen_US
dc.subjectCalcium Channel Blockersen_US
dc.subjectPlatelet-Rich Plasmaen_US
dc.subjectBone Mineral Metabolismen_US
dc.subjectHypertensionen_US
dc.titleThe effects of amlodipine and platelet rich plasma on bone healing in ratsen_US
dc.titleThe effects of amlodipine and platelet rich plasma on bone healing in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu